Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials

Background. A recombinant canarypox vector expressing human immunodeficiency virus type 1 (HIV-1) Gag, Pro, and membrane-linked gp120 (vCP1521), combined with a bivalent gp120 protein boost (AIDSVAX B/E), provided modest protection against HIV-1 infection in a community-based population in Thailand...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Montefiori, David C., Karnasuta, Chitraporn, Huang, Ying, Ahmed, Hasan, Gilbert, Peter, de Souza, Mark S., McLinden, Robert, Tovanabutra, Sodsai, Laurence-Chenine, Agnes, Sanders-Buell, Eric, Moody, M. Anthony, Bonsignori, Mattia, Ochsenbauer, Christina, Kappes, John, Tang, Haili, Greene, Kelli, Gao, Hongmei, LaBranche, Celia C., Andrews, Charla, Polonis, Victoria R., Rerks-Ngarm, Supachai, Pitisuttithum, Punnee, Nitayaphan, Sorachai, Kaewkungwal, Jaranit, Self, Steve G., Berman, Phillip W., Francis, Donald, Sinangil, Faruk, Lee, Carter, Tartaglia, Jim, Robb, Merlin L., Haynes, Barton F., Michael, Nelson L., Kim, Jerome H.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2012
Soggetti:
Major Articles and Brief Reports
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3392187/
https://ncbi.nlm.nih.gov/pubmed/22634875
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jis367
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi